Anzeige
Mehr »
Dienstag, 03.02.2026 - Börsentäglich über 12.000 News
Gold dreht wieder auf: Goldpreis-Comeback - und diese Bohrung liefert 307 Meter "Gold-System"
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A118MD | ISIN: CA12913L2030 | Ticker-Symbol:
Branche
Dienstleistungen
Aktienmarkt
Sonstige
1-Jahres-Chart
CALDWELL PARTNERS INTERNATIONAL INC Chart 1 Jahr
5-Tage-Chart
CALDWELL PARTNERS INTERNATIONAL INC 5-Tage-Chart
ACCESS Newswire
224 Leser
Artikel bewerten:
(1)

Caldwell Partners International, Inc.: Caldwell Strengthens Life Sciences and Healthcare Practice with Addition of Dr. Christoph Themel as Partner

TORONTO, ON AND LONDON, UK / ACCESS Newswire / February 3, 2026 / Retained executive search firm Caldwell (TSX:CWL)(OTCQX:CWLPF) today announced the addition of Dr. Christoph Themel as a Partner in the firm's Life Sciences and Healthcare Practice. Based in London, Dr. Themel advises boards, investors, and senior leadership teams on executive and non-executive appointments, leadership assessments, and succession planning across the pharmaceutical, biotechnology, and animal health sectors.

https://storage.googleapis.com/accesswire/media/1132337/christoph-themel.jpg

Dr. Christoph Themel joins Caldwell as partner in the firm's Life Sciences and Healthcare Practice

With more than 20 years of experience in executive search and leadership advisory, Dr. Themel is a trusted advisor to big and mid-sized pharmaceutical companies, family-owned enterprises, private equity firms, and portfolio company leadership teams across Europe, the United States, and Asia Pacific. He is particularly known for his ability to partner closely with shareholders and management teams on C-suite succession, senior-level development, and organizational effectiveness initiatives.

"Christoph brings exceptional depth in life sciences and healthcare, combined with a thoughtful, relationship-driven advisory style that resonates strongly with boards and leadership teams," said John Blank, managing partner of Caldwell's Life Sciences and Healthcare Practice. "He joins Caldwell at a moment when leadership in this sector is becoming increasingly complex and globally interconnected, so his ability to advise boards and investors on succession, organizational design, and long-term leadership capability across markets will be a significant asset to our clients and to the continued evolution of our firm."

Dr. Themel has extensive experience delivering executive search, management appraisal, and leadership development engagements in evolving and highly regulated environments. His work is characterized by a strong focus on aligning leadership capability with business strategy and culture, while fostering environments of inclusion, innovation, and impact.

Prior to joining Caldwell, Dr. Themel was a Partner in the Healthcare and Life Sciences Practice at a top-tier global executive search firm. Earlier in his career, he was a partner at a boutique executive search firm specializing in life sciences, with offices around the globe.

"Christoph's appointment reflects our continued investment in building a strong, globally integrated Life Sciences and Healthcare practice," said Chris Beck, chief executive officer. "His international experience and sector depth expand our leadership advisory capabilities and strengthen the value we deliver to clients as they navigate increasingly complex and consequential talent decisions."

??About Caldwell

Caldwell is a leading retained executive search firm connecting clients with transformational talent. Together with IQTalent, we are a technology-powered talent acquisition firm specializing in recruitment at all levels. Through the two distinct brands - Caldwell and IQTalent- the firm leverages the latest innovations in AI to offer an integrated spectrum of services delivered by teams with deep knowledge in their respective areas. Services include candidate research and sourcing through to full recruitment at the professional, executive and board levels, as well as a suite of talent strategy and assessment tools that can help clients hire the right people, then manage and inspire them to achieve maximum business results.

Caldwell's common shares are listed on The Toronto Stock Exchange (TSX:CWL) and trade on the OTCQX Market (OTCQX:CWLPF). Please visit our website at www.caldwell.com for further information.

For further information, please contact:

Caroline Lomot
Vice President, Marketing & Communications
Caldwell
clomot@caldwell.com
+1 516 830 3535

SOURCE: Caldwell Partners International, Inc.



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/business-and-professional-services/caldwell-strengthens-life-sciences-and-healthcare-practice-with-1132337

© 2026 ACCESS Newswire
Vorsicht, geheim!
2026 startet mit einem Paukenschlag: Der DAX outperformt den US-Markt, Nachzügler holen auf. Ein erstes Signal, dass der Bullenmarkt an Breite gewinnt. Während viele Anleger weiter auf die großen Tech-Namen setzen, hat sich im Hintergrund längst ein Umschwung vollzogen. Der Fokus verschiebt sich weg von überteuerten KI-Highflyern hin zu soliden Qualitätswerten aus der zweiten Reihe.

Anleger, die jetzt clever agieren, setzen nicht auf das, was war, sondern auf das, was kommt. Unternehmen mit gesunder Bilanz, unterschätztem Potenzial und begrenztem Abwärtsrisiko könnten 2026 zu den großen Gewinnern zählen. Die Gefahr einer schärferen Korrektur bleibt real, gerade für passiv aufgestellte Investoren.

In unserem neuen Spezialreport stellen wir fünf Aktien vor, die genau jetzt das Potenzial für überdurchschnittliche Renditen bieten. Stark, günstig und bislang kaum im Fokus.

Jetzt kostenlosen Report herunterladen – bevor es andere tun!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.